Chong Kun Dang Pharmaceutical Corp.
185750 | KO
Overview
Corporate Details
- ISIN(s):
- KR7185750007
- LEI:
- Country:
- South Korea
- Address:
- 서울 서대문구 충정로3가 3가 368 종근당빌딩, 서대문구
- Website:
- https://www.ckdpharm.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-29 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (텔미누보정(CKD828) 식품의약품안전처 국내 품목허가 승인)
|
Korean | 7.2 KB | ||
| 2025-08-22 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (텔미누보정(CKD828) 식품의약품안전처 국내 품목허가 신청)
|
Korean | 13.5 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 4.9 MB | ||
| 2025-08-01 00:00 |
Earnings Release
영업(잠정)실적(공정공시)
|
Korean | 13.3 KB | ||
| 2025-07-24 00:00 |
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
|
Korean | 15.8 KB | ||
| 2025-06-24 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 99.9 KB | ||
| 2025-06-12 00:00 |
Regulatory Filings
유형자산취득결정
|
Korean | 7.9 KB | ||
| 2025-06-12 00:00 |
Regulatory Filings
풍문또는보도에대한해명(미확정)
|
Korean | 8.0 KB | ||
| 2025-06-10 00:00 |
Regulatory Filings
풍문또는보도에대한해명(미확정)
|
Korean | 6.2 KB | ||
| 2025-06-02 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 1.8 MB | ||
| 2025-05-22 00:00 |
Regulatory Filings
기타경영사항(자율공시) (CKD510 기술수출 관련 마일스톤 수령)
|
Korean | 5.2 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 2.9 MB | ||
| 2025-04-30 00:00 |
Earnings Release
영업(잠정)실적(공정공시)
|
Korean | 13.3 KB | ||
| 2025-04-23 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (듀비엠폴서방정(CKD383) 식품의약품안전처 국내 품목허가 신청)
|
Korean | 16.9 KB | ||
| 2025-04-23 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (듀비엠파정(CKD398) 식품의약품안전처 국내 품목허가 신청)
|
Korean | 16.6 KB |
Automate Your Workflow. Get a real-time feed of all Chong Kun Dang Pharmaceutical Corp. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Chong Kun Dang Pharmaceutical Corp.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Chong Kun Dang Pharmaceutical Corp. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.
South Korea
067370
South Korea
067370
Develops novel oncology/antiviral drugs and commercializes generic pharmaceuticals in Canada.
United States of America
SBFM
United States of America
SBFM
Develops and commercializes therapies for CNS diseases like epilepsy, migraine, and ADHD.
United States of America
SUPN
United States of America
SUPN
Provides medical device coatings, vascular products, and components for diagnostic tests.
United States of America
SRDX
United States of America
SRDX
Develops engineered cancer drugs like ADCs using a cell-free protein synthesis platform.
United States of America
STRO
United States of America
STRO
/other/Swedencare_AB_publ-logo.png){kind=logo}
Develops and markets premium health supplements and pharmaceuticals for cats, dogs, and horses.
Sweden
SECARE
Sweden
SECARE
Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.
Sweden
SOBI
Sweden
SOBI
Acquires and commercializes specialty drugs for unmet needs in Japan and the Asia-Pacific region.
Japan
4582
Japan
4582
Biotech developing oral therapies to resolve inflammation in diseases like rheumatoid arthritis.
Sweden
SYNACT
Sweden
SYNACT
Developing inhaled interferon beta treatments for severe viral lung infections in hospitalized patients.
United Kingdom
SNG
United Kingdom
SNG